Moreover, the authors also showed that both in ovarian cancer animal model and in patients with ovarian cancer, blocking IL-6 production with small interfering RNA or siltuximab, an anti-IL-6 antibody, respectively, normalized platelet counts. Here, IL6 is linked to ovarian carcinoma.